explore -WSS

explore

author：hotspot 2025-09-29 01:09:25 - browse：1

Seng Cheng has been working in gene therapy for nearly as long as gene therapy has been a field. As a young scientist in the early 1990s, he was part of one of three teams racing to develop a gene therapy for cystic fibrosis, a high-profile effort that resulted in national headlines, prestigious publications, and zero patients cured.

So he’s seen the field’s highs and lows. Lately, there have been a lot of both, including at Pfizer, the company Cheng called home until this summer. The pharma brought three potentially powerful gene therapies for muscular dystrophy and hemophilia into late-stage trials but, in January, chose to abandon a large portfolio of early stage candidates that relied on the same technology: adeno-associated viruses, or AAVs, a group of small bugs that scientists spent two decades taming into a gene shipping system.

The move seemed emblematic. Across the industry, AAV companies have been struggling, either shelving programs or stopping work altogether, while investors shuttled money toward new technologies such as CRISPR and its various permutations. Longtime researchers feared promising drugs, particularly for ultra-rare diseases, might get lost in the shuffle.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： All of Us, NIH's precision medicine initiative, gets a big boost

focus

hotspot

WSS

Medicare proceeds with plan to claw back hospital funds

Key Senate panel to consider PBM, drug pricing reform package

How to keep neuroscience’s past racism from being its future

Travis Kelce and the trap of celebrity vaccine endorsements

How to convince healthy people to buy insurance

What is microchimerism and how does it affect maternal health?

knowledge

explore

focus

Trump demands the U.S. pay no more for drugs than other countries … again

Keeping primary care docs in field isn't impossible, says AAFP CEO

Peter Hotez and the public health issue of online harassment

After Sarepta trial failure, Duchenne families brace for more debate

Psychedelics group wrestles with new pharma identity

Readout LOUD podcast: ESMO highlights & Roivant's big deal

United colonoscopy coverage change 'may cost lives,' doctors say

David Ricks of Eli Lilly: best biopharma CEO of 2023

Heart attack and stroke risk calculators need revising

Brain injuries and the importance of a second opinion

knowledge

Explaining an after

David Ricks of Eli Lilly: best biopharma CEO of 2023

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

Brain injuries and the importance of a second opinion

CRISPR gene editing developments we’re watching in 2024

How to keep neuroscience’s past racism from being its future

Wikipedia

focus

hotspot

knowledge